Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.

Abstract

Over the past year, interferon (IFN) free dosing regimens have become available to treat chronic hepatitis C. Offering high rates of sustained virological response (SVR), short treatment and improved tolerability, IFN-free treatment now represents the paradigm for both treatment-naïve and -experienced patients. Patients with prior treatment failure, in particular those with cirrhosis, still represent some of the most difficult to treat, but the availability of multiple agents that can interrupt several steps of the HCV lifecycle affords providers and patients with options that can be combined and individually tailored to each patient's unique needs to obtain high rates of SVR.

• Authors: Joy Peter, David R Nelson
• Journal: Liver international : official journal of the International Association for the Study of the Liver (Liver Int) Vol. 35 Suppl 1 Pg. 65-70 (Jan 2015) ISSN: 1478-3231 [Electronic] United States
• PMID: 25529089 (Publication Type: Journal Article, Review)
• Copyright: © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Antiviral Agents
• Benzimidazoles
• Carbamates
• Fluorenes
• Imidazoles
• Pyrrolidines
• ledipasvir
• Uridine Monophosphate
• Valine
• daclatasvir
• Sofosbuvir

Topics

• Antiviral Agents (therapeutic use)
• Benzimidazoles (therapeutic use)
• Carbamates
• Drug Therapy, Combination (methods, trends)
• Fluorenes (therapeutic use)
• Genotype
• Hepacivirus (drug effects)
• Hepatitis C, Chronic (drug therapy, genetics)
• Humans
• Imidazoles (therapeutic use)
• Precision Medicine (methods, trends)
• Pyrrolidines
• Sofosbuvir
• Uridine Monophosphate (analogs & derivatives, therapeutic use)
• Valine (analogs & derivatives)